******************************************************** to unsubscribe, simply reply to this email, thanks. ********************************************************
TIDES 2003 TO ATTRACT OVER 400 PEOPLE HIGHLY REGARDED INDUSTRY EXPERTS TO DELIVER KEYNOTE PRESENTATIONS Westborough, MA, April 1, 2003 – In continuing with its many years of tradition, TIDES® 2003 will again attract over 400 people when it convenes from April 28 - May 1, 2003 in Las Vegas, NV. The main event, which includes IBC's 7th International Oligonucleotide Technology Conference and the 6th International Peptide Technology Conference, features the following keynote presentations from acknowledged industry experts: Prospects for the Oligonucleotide-Based Drugs in Development Professor C.A. Stein, M.D., Ph.D., Professor of Medicine, Urology and Molecular Pharmacology, Albert Einstein College of Medicine At the present time, two phosphorothioate antisense oligonucleotides are in Phase III clinical trials. Genasesne is being evaluated in advanced melanoma, myeloma, and chronic lymphocytic leukemia, with and without (in the case of CLL) cytotoxic chemotherapy. Affinitak (a.k.a. Isis 3521) is being evaluated by Isis in collaboration with Eli Lilly in advanced non-small cell lung cancer, in combination with cytotoxic chemotherapy. Data analysis is anticipated by the second quarter of '03. These critical trials, and important mechanistic questions that they raise, will be discussed. Drug Development Case History: Exenatide (AC2993; Synthetic Exendin-4) Andrew A. Young, M.D., Ph.D., Vice President and Senior Research Fellow, Amylin Pharmaceuticals Inc. Exenatide (synthetic exendin-4), a 39 amino acid peptide currently being explored as an antidiabetic therapy in patients with type 2 diabetes, exhibits many of the actions of the human hormone, glucagon-like peptide-1 (GLP-1). But some key attributes not shared with GLP-1 have promoted its success as a drug development candidate. Plasma stability and high in vivo potency have resulted in multiple favorable pharmaceutical properties, including for example, the enablement of non-injectable and/or long-acting formulations. Other topics in the 2003 TIDES® agenda include updates on therapeutics in late-stage clinical development, formulation and delivery, large-scale synthesis and purification for peptide and oligonucleotide-based therapeutics, high-throughput chemistry for research applications, considerations for diagnostic applications, PLUS a new session on analytical characterization of oligo- and peptide-based therapeutics. Interactive focus groups, a new Start-Up showcase and more will also take place. ATTENTION CALENDAR EDITORS! For more information on attending TIDES® 2003 Oligonucleotide and Peptide Technology Conferences from April 28 - May 1, 2003 at the Mandalay Bay Resort & Casino in Las Vegas, NV, visit http://www.lifesciencesinfo.com/TIDES; call 508-616-5550 or e-mail mailto:[EMAIL PROTECTED] ABOUT IBC LIFE SCIENCES IBC Life Sciences, a part of the Informa Group plc - the leading provider of scientific, technological and business information to the global life science community - offers quality learning and networking events, and has established industry-leading North American and European events in three primary market sectors: Drug Discovery, Microtechnology, and Biopharmaceutical Production. Other members of the Group include: D&MD, publisher of D&MD Newsletter and Bioprocess News, in addition to its line of D&MD Reports, Executive Briefings, Focus Reports, and How-To Guides; Eaton Publishing Co., publisher of BioTechniques(R), the leading peer-reviewed international journal of laboratory technology for bioresearch; and BioProcess International(TM), devoted to the development, scale-up, and manufacture of biotherapeutics. Learn more at www.lifesciencesinfo.com. ******************************************************** This segmented email list tends to serve the people who are interested in news and product info in Peptide sector. To unsubscribe, simply reply to this email. To distribute your releases to this list, contact [EMAIL PROTECTED] To order market report "Cancer Immunotherapy Beyond Monoclonals" from Biotaq.com at: http://www.biotaq.com/onsale/biotaqreports.htm BIOTAQ.COM's email Newswire service is focused exclusively on biotech industry. Edit or change your interest category selections at: https://www.biotaq.com/interests.htm ************************************************************************** ** _______________________________________________ Biojava-l mailing list - [EMAIL PROTECTED] http://biojava.org/mailman/listinfo/biojava-l
